Shopping Cart
Professional article · Chronic wounds
PRP for chronic wounds: Evidence, clinical use and limitations
Platelet-rich plasma (PRP) is being investigated as an adjunctive approach for hard-to-heal wounds. New meta-analyses and randomized studies from 2025 and 2026 report positive signals for several wound types. At the same time, guidelines remain cautious – mainly because PRP preparations differ, protocols are heterogeneous and standardization is limited.
Evidence update · As of 3 September 2026Why chronic wounds are so difficult
A chronic wound is not an isolated surface problem. What matters is why normal healing is impaired.
Wound healing takes place in overlapping phases. Hemostasis, the inflammatory response, cell migration, angiogenesis, matrix formation and later tissue remodeling must be coordinated over time. Diabetes, arterial or venous vascular disease, repeated pressure, infection or other comorbidities can disrupt this process.
Treatment therefore starts with identifying the cause of impaired healing. A local adjunctive procedure cannot compensate for relevant ischemia, persistent pressure or an inadequately treated infection.
Hemostasis
Platelets and the coagulation system respond immediately to tissue injury.
Inflammation
Immune cells clear damaged tissue and respond to possible pathogens.
Proliferation
Granulation tissue, blood vessels and a new surface covering develop.
Remodeling
The newly formed tissue is structurally reorganized over a longer period.
A chronic wound requires treatment of its cause.
Vascular status, pressure distribution, signs of infection, metabolic status and previous wound management should be assessed professionally before any adjunctive therapy.
Why platelets are interesting for wound healing
Platelets are involved in more than coagulation. After activation they release numerous biologically active mediators.
PRP is obtained from the patient’s own blood. After centrifugation, a plasma fraction is obtained whose composition may vary considerably depending on the system and protocol. Activated platelets release PDGF, TGF-β and VEGF, among other signaling molecules involved in cell migration, angiogenesis and matrix remodeling.
This biological plausibility explains the research interest. By itself, however, it does not prove clinical treatment success. Whether PRP provides an additional benefit has to be investigated clinically for the respective wound type, the specific preparation and the mode of application.
More on the biological background: Why platelets matter to dermatologists.
The term “PRP” does not describe a uniform formulation.
Results from one study protocol therefore cannot automatically be transferred to another tube, centrifuge or application method.
PRP is an adjunctive procedure – not the basic therapy
The benefit of local procedures can only be assessed meaningfully if the main causes of the wound are treated in parallel.
Step 1
Clarify the cause of the wound
Assess wound type, perfusion, venous status, pressure load, signs of infection and comorbidities.
Step 2
Ensure standard wound care
Depending on the wound type, debridement, appropriate dressings, pressure relief, compression, infection control or revascularization form part of the foundation.
Step 3
Classify adjunctive procedures
Only then can it be assessed whether an autologous preparation may be a useful adjunct in a defined clinical situation.
Evidence update 2025/2026: what the studies actually show
The evidence base is broader than it was only a few years ago. Its strength still differs by wound type.
The evidence base is most extensive for diabetic foot ulcers. New meta-analyses also report positive signals for venous ulcers and pressure ulcers. These results are relevant, but they do not justify the blanket statement “PRP heals chronic wounds”.
Diabetic foot ulcers Most extensive positive evidence; guideline still cautious.
15 RCTsMeta-analysis Xu et al. 2025
1.010patients included
RR 1,53for complete healing compared with conventional care
The meta-analysis by Xu, Huang and Tao also reported a mean healing time shorter by 19.48 days. Infection and amputation rates were also lower in the pooled analysis. This is a relevant study signal, but not a guarantee for an individual patient and not a universal recommendation for every PRP protocol.
Venous ulcers New 2026 meta-analysis positive, but with relevant heterogeneity.
13 studiesMeta-analysis Rodrigues-Guimarães et al. 2026
554patients included
1,50pooled ratio for complete healing; 95% CI 1.09–2.07
The analysis found better healing outcomes with PRP. At the same time, heterogeneity was I² = 58% for complete healing and I² = 97% for wound area reduction. The authors therefore call for further high-quality, larger randomized studies.
Pressure ulcers / decubitus ulcers Positive RCT meta-analysis, but independent confirmation is still needed.
9 RCTsMeta-analysis Hu et al.; online 2024, issue 2026
511patients with a total of 523 pressure ulcers
OR 3,40pooled healing rate; 95% CI 1.87–6.21
The authors report a higher healing rate and improvements in individual wound measurements. For complications and volume reduction, not all analyses showed significant differences. Despite the positive signal, further well-designed RCTs are needed.
PubMed: Hu et al., International Journal of Lower Extremity Wounds
Other chronic wounds No blanket transfer from studies on diabetic, venous or pressure ulcers.
Chronic wounds have different causes. Results from one defined wound type should not simply be transferred to arterial ulcers, postoperative wound-healing disorders, inflammatory ulcers or other complex wound conditions.
Statistical improvement and a guideline recommendation are not the same thing.
Guidelines also consider study quality, risk of bias, comparability of preparations, practical feasibility and integration into standard wound care.
More platelets do not automatically mean better wound healing
A randomized study from 2026 questions the simple equation “higher concentration = better effect”.
A randomized non-inferiority study published in 2026 in the Journal of the American Academy of Dermatology compared, in 56 people with diabetic wounds, a preparation with approximately physiological platelet concentration (1× baseline) with more concentrated PRP (4× baseline). All participants were scheduled for debridement and suturing; infection, ischemia, stasis and shear forces had been treated beforehand.
4-week healing rate in this study
The physiological concentration was non-inferior to the 4× concentrated PRP for the primary endpoint.
Important: this was a small, single-center study in a specific surgical setting. The results do not prove that 1× is generally better than 4× or that the finding can be transferred to other PRP applications.
The study highlights a central point in PRP research: the quality of a preparation cannot meaningfully be defined by achieving the highest possible platelet count alone. Composition, activation, fibrin structure, starting material and clinical context also play a role. View the study on PubMed.
PRP reaches specialized wound centers in Germany
A current real-world example shows that the topic is no longer discussed only in studies.
Clinical example · 1 September 2026
Helios Klinikum Krefeld reports using PRP for hard-to-heal and diabetic wounds
Helios Klinikum Krefeld reports that its Department of Dermatology uses PRP in the certified wound center for hard-to-heal and diabetic wounds. Care is interdisciplinary, involving dermatology, angiology, vascular surgery, plastic surgery and the diabetic foot clinic.
For scientific interpretation, one point is crucial: use at a specialized center is a clinical example, not proof of efficacy. Clinical use does not establish a general recommendation or superiority over guideline-based standard wound care.
Why this example is still relevant
It shows that platelet-based procedures are increasingly appearing in specialized clinical care structures. Controlled studies and guidelines remain decisive when assessing benefit.
Why the IWGDF guideline remains cautious
The current guideline position is the most important counterweight to the positive meta-analyses.
The current IWGDF guideline on interventions to enhance healing in diabetes-related foot ulcers assesses autologous platelet preparations in a differentiated way. With the exception of a defined autologous leukocyte-platelet-fibrin patch, it suggests not routinely using autologous platelet therapies as an adjunct to standard care. The recommendation is conditional and based on low-certainty evidence.
This caution does not necessarily contradict more recent positive studies. Guidelines must assess whether an effect is robust, reproducible and practically standardizable across different preparations and protocols.
Study level
Several current meta-analyses report better healing outcomes with PRP in defined chronic wounds.
Guideline level
There is still no routine recommendation for general autologous platelet preparations. Standard care and a clear indication remain decisive.
Hygiene and process safety are part of treatment
Autologous does not automatically mean risk-free. A standardized workflow is particularly important with open wounds.
A 2026 publication on infection prevention in PRP documented differences between clinical areas in labeling, centrifugation, handling and application. The authors developed a standardized SOP approach and emphasize collaboration between clinicians, infection prevention, blood safety and quality assurance.
Possible burdens and risks
Blood collection, local pain, bleeding and application-related complications are possible. With open wounds, process hygiene has additional importance.
Standardized procedures
Identification, labeling, centrifugation, aseptic handling, application and documentation should be regarded as one connected process.
Technical PRP preparation: reproducible rather than one-size-fits-all
Tubes, centrifuge, rotor, adapters and process parameters influence the resulting fraction – but they do not prove clinical efficacy.
For professional users, it is important that PRP tubes, PRP centrifuge, rotor, adapters and process parameters are technically compatible. The intended purpose, current instructions for use and validated workflows of the responsible medical institution remain decisive.
PRP tubes · Item 100101
Vi PRP-PRO
Sterile tube system for professional PRP preparation with sodium citrate and separator gel. The product data describe the technical workflow, not the treatment of a specific wound indication.
- Class IIa medical device, CE 0425
- approx. 9 ml intended blood draw volume
- 0.8 ml sodium citrate and separator gel
- technical standard value: 1200 × g for 7 minutes
Medical device centrifuge · Item 100347
Hettich EBA 200 MD
Compact medical device centrifuge for professional facilities. RCF, RPM and runtime must match the tube system used and the validated protocol.
- Class IIa medical device
- 8-place fixed-angle rotor E3694
- maximum capacity 8 × 15 ml
- RCF, RPM and runtime adjustable
Do not transfer RPM settings without checking RCF
The same RPM does not produce the same relative centrifugal force with different rotor radii. Protocols should therefore be assessed technically in terms of RCF, radius, rotor, adapters and runtime. Calculate RCF and RPM.
Where the limits of the evidence lie
The specific wound and its cause matter more than the general label “PRP therapy”.
With diabetic foot ulcers, the underlying cause may persist without adequate pressure relief or when arterial perfusion impairment remains untreated. In venous ulcers, venous pathophysiology matters; in pressure ulcers, consistent pressure relief is essential. Infections require separate professional treatment.
Another issue is the lack of standardization of PRP preparations. Concentration, cell content, activation, fibrin structure and route of application can differ considerably between studies. Results therefore cannot simply be transferred between systems.
The statement “PRP heals chronic wounds” would be scientifically too broad.
A more accurate statement is: for certain chronic wound types, there is an increasing amount of positive clinical data on PRP as an adjunctive procedure. The evidence, guideline position and transferability nevertheless depend on wound type and protocol.
Frequently asked questions about PRP for chronic wounds
Brief answers without blanket healing promises.
Is PRP a standard therapy for chronic wounds?
No. PRP is being investigated as an adjunctive approach and is used in some specialized facilities. Treatment of the underlying cause and guideline-based standard wound care remain the foundation.
For which wound type is the evidence most extensive?
Among the wound types discussed here, the most extensive clinical evidence is available for diabetic foot ulcers. Positive meta-analyses are now also available for venous ulcers and pressure ulcers.
Does the IWGDF recommend PRP for diabetic foot ulcers?
The IWGDF guideline does not recommend routine use of general autologous platelet preparations as an adjunct to standard care. A defined autologous leukocyte-platelet-fibrin patch is assessed separately.
Does a higher platelet concentration automatically mean a better effect?
No. In a specific setting, a randomized 2026 study found no superiority of 4× concentrated PRP over a preparation with physiological platelet concentration. The optimal composition has still not been conclusively established.
What does the example of Helios Klinikum Krefeld show?
It shows that PRP is now also being used for hard-to-heal and diabetic wounds in a specialized German wound center. This is a clinical example, not proof of general efficacy or a guideline recommendation.
Why is PRP preparation so important?
PRP preparations differ depending on the tube, centrifugation, cell content, activation and mode of application. A reproducible technical workflow is therefore important for documentation and comparability.
As of 3 September 2026: more interesting than a few years ago – but not a blank cheque
The evidence on PRP for chronic wounds has broadened. Numerous randomized data are now available for diabetic foot ulcers; current meta-analyses also show positive signals for venous ulcers and pressure ulcers. At the same time, the IWGDF remains cautious regarding general autologous platelet preparations. The current example from Helios Klinikum Krefeld shows increasing clinical implementation, but does not replace controlled evidence. Treating the cause of the wound and providing appropriate standard wound care remain decisive.
Selected professional sources
- Wilkinson HN, Hardman MJ. Wound healing: cellular mechanisms and pathological outcomes. Open Biology. 2020. PubMed Central
- Xu H, Huang K, Tao X. Efficacy and safety of platelet-rich plasma versus conventional care in diabetic foot ulcers: a meta-analysis of randomized controlled trials. Acta Diabetologica. 2025;62(10):1585–1596. DOI 10.1007/s00592-025-02555-7. PubMed
- Rodrigues-Guimarães T, Horta R, Marques-Vieira M, Andrade J, Rocha-Neves J. Meta-analysis of platelet-rich plasma for venous ulcers: Clinical efficacy and complications. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2026;114:212–224. DOI 10.1016/j.bjps.2026.01.020. PubMed
- Hu Z, Xv H, Feng A, Wang S, Han X. Efficacy and Safety of Platelet-Rich Plasma for Pressure Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. International Journal of Lower Extremity Wounds. 2026;25(1):45–54. DOI 10.1177/15347346241227001. PubMed
- Li Y, Zhang J, Yang Z et al. Physiological-concentration Platelet Fibrin Plasma vs. Supra-Physiological-concentration Platelet Rich Plasma for Neuro-ischemic Diabetic Foot Ulcer and other Diabetic Wounds: A Randomized Controlled Trial. Journal of the American Academy of Dermatology. 2026. DOI 10.1016/j.jaad.2026.07.025. PubMed
- Parsa H, Haji Maghsoudi L, Mohammadzadeh A, Afshar H. A Comparative Study on the Effect of PRP in Healing Diabetic Foot Ulcers Compared to Standard Treatment in Diabetic Patients: A Randomized Clinical Trial Study. Health Science Reports. 2026;9(3):e71906. DOI 10.1002/hsr2.71906. PubMed
- International Working Group on the Diabetic Foot (IWGDF). Guidelines on interventions to enhance healing of foot ulcers in people with diabetes. 2023 update. Guideline
- Stern RA, Andrews J, Bashaw K, Talbot TR. Platelet-rich plasma therapy: key infection prevention practices and strategies for safety risk reduction. Infection Control & Hospital Epidemiology. 2026;47(1):1–5. DOI 10.1017/ice.2025.10316. PubMed
- Helios Klinikum Krefeld. Mit Eigenblut chronische Wunden behandeln: die PRP-Therapie am Helios Klinikum Krefeld. Pressemitteilung vom 01.09.2026. Original source
Note on literature selection: Two frequently cited meta-analyses on PRP for diabetic wounds from the International Wound Journal were retracted in 2025 following an investigation of the peer-review process and were not used as evidence sources for this update (PubMed PMID 40118527 and 40118538).
PRP for diabetic foot ulcersIn-depth review of the evidence and clinical classification for diabetic foot ulcers.
Platelets in dermatologyBiological background on hemostasis, signaling molecules and tissue repair.
RCF/RPM calculatorTechnical conversion of centrifugal force, rotational speed and rotor radius.
Medical note:
This article is intended for professional information and reflects the scientific discussion up to 3 September 2026. It does not replace wound assessment, an individual medical diagnosis, treatment decision, instructions for use or an internal SOP. Statements about study results refer to the populations and procedures investigated and should not be understood as promises of success.